Read by QxMD icon Read

Journal of Parkinson's Disease

Makoto Hashimoto, Gilbert Ho, Yoshiki Takamatsu, Yuka Shimizu, Shuei Sugama, Takato Takenouchi, Masaaki Waragai, Eliezer Masliah
At present, the precise physiological role of neurodegenerative disease-related amyloidogenic proteins (APs), including α-synuclein in Parkinson's disease and β-amyloid in Alzheimer's disease, remains unclear. Because of similar adaptability of both human brain neurons and yeast cells to diverse environmental stressors, we previously proposed that the concept of evolvability in yeast prion could also be applied to APs in human brain. However, the mechanistic relevance of evolvability to neurodegenerative disorders is elusive...
July 11, 2018: Journal of Parkinson's Disease
K Grace Cannard, Mallory Hacker, Anna Molinari, Lauren E Heusinkveld, Amanda D Currie, David Charles
BACKGROUND: Clinical trials are often hindered by inadequate patient recruitment. Overly optimistic investigator predictions of participation can lead to unmet recruitment goals and costly trial extensions. A patient-focused approach estimating recruitment in clinical trials may provide higher accuracy. OBJECTIVE: To predict the feasibility of recruitment in a future deep brain stimulation (DBS) in early-stage Parkinson's disease (PD) multicenter trial by understanding motivations and concerns to participation of past and potential future DBS in early-stage PD clinical trial subjects...
June 27, 2018: Journal of Parkinson's Disease
Rivka Inzelberg, Alejandro Estrada-Cuzcano, Yael Laitman, Els De Vriendt, Eitan Friedman, Albena Jordanova
Kufor-Rakeb syndrome (KRS)/PARK9 presents with autosomal recessive young onset Parkinson's disease (YOPD), spastic paraparesis, abnormal eye movements and facial myokymia. KRS is caused by homozygous/compound heterozygous inactivating mutations in ATP13A2. Two affected siblings (born to non-consanguineous Jewish parents) presenting a similar KRS phenotype (onset age 27, 23), carried compound heterozygous pathogenic variants in ATP13A2: c.217_218insG and c.3057delC. Allele frequency of the c.3057delC mutation was about 100 times higher in Ashkenazi controls in our study (1/190 = 0...
June 23, 2018: Journal of Parkinson's Disease
David J McGee, Xiao-Hong Lu, Elizabeth A Disbrow
While a small subset of Parkinson's disease cases have genetic causes, most cases are sporadic and may have an environmental contributor that has largely remained enigmatic. Remarkably, gastrointestinal symptoms in PD patients serve as a prodrome for the eventual motor dysfunctions. Herein, we review studies exploring a possible link between the gastric human pathogen Helicobacter pylori and PD. We provide plausible and testable hypotheses for how this organism might contribute to PD: 1) a toxin(s) produced by the bacteria; 2) disruption of the intestinal microbiome; 3) local inflammation that crosses the gut-brain axis, leading to neuroinflammation; and 4) manipulation of the pharmacokinetics of the PD drug levodopa by H...
June 23, 2018: Journal of Parkinson's Disease
Anindita Bose, Gregory A Petsko, David Eliezer
Parkinson's disease (PD) is a neurodegenerative disorder that is characterized by loss of dopaminergic neurons in the substantia nigra pars compacta, depletion of dopamine in the striatum and the presence of Lewy bodies. Cancer is uncontrolled growth of cells in the body and migration of these cells from their site of origin to other parts of the body. PD and cancer are two opposite diseases, one arising from cell proliferation and the other from cell degeneration. This fundamental difference is consistent with inverse comorbidity between most cancers and neurodegenerative diseases...
June 9, 2018: Journal of Parkinson's Disease
Stephen Polgar, Leila Karimi, Melissa Buultjens, Meg E Morris, Monica Busse
Evidence from a growing number of preclinical studies indicate that recently discovered stem cell lines may be translated into viable cellular therapies for people with Parkinson's disease. In a brief but critical review, we examine the use of primary and secondary outcome measures currently used to evaluate the efficacy of cellular therapies. The current practice of relying on a single primary outcome measure does not appear to provide the evidence required for demonstrating the robust, life-changing recovery anticipated with the successful implementation of cellular therapies...
June 5, 2018: Journal of Parkinson's Disease
(no author information available yet)
No abstract text is available yet for this article.
March 26, 2018: Journal of Parkinson's Disease
Elliot Hogg, Kishore Athreya, Christina Basile, Echo E Tan, Jan Kaminski, Michele Tagliati
BACKGROUND: Reduced glucose tolerance has been long recognized as a potential risk factor for Parkinson's disease (PD), and increasing scrutiny is currently being placed on insulin resistance (IR) as a pathologic driver of neurodegeneration. However, the prevalence of IR in PD is unknown. OBJECTIVE: To determine IR prevalence in non-diabetic patients with PD and to correlate IR with other metabolic indicators, motor and non-motor symptoms (NMS) of PD, and quality of life (QoL)...
March 26, 2018: Journal of Parkinson's Disease
Michela Balconi, Chiara Siri, Nicoletta Meucci, Gianni Pezzoli, Laura Angioletti
BACKGROUND: Pathological gambling (PG) in Parkinson's disease (PD) manifests as a persistent and uncontrollable gambling behavior, characterized by dysfunctional decision-making and emotional impairment related to high-risk decisions. OBJECTIVE: The aim of this study was to explore the relationship between personality traits and prefrontal cortex activity in PD patients with or without PG. METHODS: Thus, hemodynamic cortical activity measured by functional near-infrared spectroscopy (fNIRS) and Iowa Gambling Task (IGT) performance were recorded in forty-six PD patients, divided into three groups according to their gambling status: PD patients with active gambling behavior (PDG); PD patients who remitted from PG (PDNG); and a control group (CG) composed by patients with PD only...
March 26, 2018: Journal of Parkinson's Disease
Hai-Yan Zhou, Pei Huang, Qian Sun, Juan-Juan Du, Shi-Shuang Cui, Yu-Yan Tan, Yun-Yun Hu, Wei-Wei Zhan, Ying Wang, Qin Xiao, Jun Liu, Sheng-Di Chen
BACKGROUND: It is debatable whether transcranial sonography (TCS) could be a biomarker for monitoring disease progression. Various phenotypes of Parkinson's disease (PD) may be a major reason contributing to the inconsistency. OBJECTIVE: We classified PD patients into different subtypes and evaluated the correlation between SN echogenicity and disease progression. METHODS: A total of 411 PD patients were included in this study. TCS evaluations of the substantia nigra (SN) were performed, and motor and non-motor symptoms were assessed by a series of rating scales in all PD patients...
March 26, 2018: Journal of Parkinson's Disease
Hamad Alzahrani, Annalena Venneri
BACKGROUND: Cognitive impairments are the most common non-motor symptoms in Parkinson's disease (PD). These symptoms have a negative impact on patients' quality of life and daily living activities. This review will focus on published articles that investigated the efficacy of cognitive rehabilitation in PD. OBJECTIVES: To review the existing literature on the efficacy of cognitive rehabilitation in PD and highlight the most effective form of intervention to prevent cognitive decline...
March 26, 2018: Journal of Parkinson's Disease
Irene Katsaiti, John Nixon
BACKGROUND: A qualified consensus suggests that a combination of levodopa with a peripherally acting dopa decarboxylase inhibitor continues to present the gold standard treatment of Parkinson's disease (PD). However, as the disease progresses the therapeutic window of levodopa becomes narrowed. Pharmacological strategies for motor fluctuations are focused on providing less pulsatile and more continuous dopaminergic stimulation. Peripheral catechol-O-methyltransferase (COMT) inhibition improves the bioavailability of levodopa and results in a prolonged response...
March 26, 2018: Journal of Parkinson's Disease
Sheikh Momin, Philipp Mahlknecht, Dejan Georgiev, Thomas Foltynie, Ludvic Zrinzo, Marwan Hariz, Andre Zacharia, Patricia Limousin
BACKGROUND: Whilst changes in the frequency of subthalamic deep brain stimulation (STN-DBS) have been proposed to improve control of tremor or axial motor features in Parkinson's disease (PD), little is known about the effects of frequency changes on upper limb motor function, particularly bradykinesia. OBJECTIVE: To investigate the acute effects of various STN-DBS frequencies (40-160 Hz, 40 Hz intervals) on upper limb motor function. METHODS: We carried out a randomised, double-blind study on 20 PD patients with chronic STN-DBS using the Simple and Assembly components of the Purdue Pegboard (PP) test and a modified upper limb version of the UPDRS-III (UL-UPDRS-III)...
March 26, 2018: Journal of Parkinson's Disease
Nicole K Polinski, Laura A Volpicelli-Daley, Caryl E Sortwell, Kelvin C Luk, Nunilo Cremades, Lindsey M Gottler, Jessica Froula, Megan F Duffy, Virginia M Y Lee, Terina N Martinez, Kuldip D Dave
Parkinson's disease (PD) is the second most common neurodegenerative disease, affecting approximately one-percent of the population over the age of sixty. Although many animal models have been developed to study this disease, each model presents its own advantages and caveats. A unique model has arisen to study the role of alpha-synuclein (aSyn) in the pathogenesis of PD. This model involves the conversion of recombinant monomeric aSyn protein to a fibrillar form-the aSyn pre-formed fibril (aSyn PFF)-which is then injected into the brain or introduced to the media in culture...
January 30, 2018: Journal of Parkinson's Disease
Mandy Roheger, Elke Kalbe, Inga Liepelt-Scarfone
BACKGROUND: Cognitive dysfunction is one of the most prevalent non-motor symptoms in Parkinson's disease (PD), often experienced as more debilitating for patients and caregivers than motor problems. Therefore, a deeper understanding of the course of cognitive decline and the identification of valid progression markers for Parkinson's disease dementia (PDD) is essential. OBJECTIVE: This systematic review summarizes the current state of knowledge on cognitive decline over time by reporting effect sizes of cognitive changes in neuropsychological tests...
2018: Journal of Parkinson's Disease
Dilan Athauda, Kate Maclagan, Natalia Budnik, Luca Zampedri, Steve Hibbert, Simon S Skene, Kashfia Chowdhury, Iciar Aviles-Olmos, Patricia Limousin, Thomas Foltynie
BACKGROUND: Exenatide is a GLP-1 receptor agonist that was recently studied for potential disease-modifying effects in a randomised, placebo-controlled clinical trial in patients with moderate stage Parkinson's disease, and showed positive effects on the motor severity of the disease which were sustained 12 weeks beyond the period of exenatide exposure. Analysis of pre-defined secondary outcomes revealed no statistically significant differences between patients treated with exenatide in total non-motor symptom burden and overall quality of life measures...
2018: Journal of Parkinson's Disease
Etienne Goubault, Hung P Nguyen, Sarah Bogard, Pierre J Blanchet, Erwan Bézard, Claude Vincent, Mélanie Langlois, Christian Duval
BACKGROUND: Clinical and anecdotal observations propose that patients with Parkinson's disease (PD) may show drug-induced dyskinesia (DID) concomitantly with cardinal motor features. However, the extent of the concomitant presence of DID and cardinal features remains to be determined. OBJECTIVES: This cross-sectional study measured peak-dose choreic-type DID in a quantitative manner in patients diagnosed with PD, and determined whether symptoms such as tremor, bradykinesia, rigidity, postural instability or freezing of gait (FoG) were still detectable in these patients...
2018: Journal of Parkinson's Disease
Viswas Dayal, Timothy Grover, Patricia Limousin, Harith Akram, Davide Cappon, Joseph Candelario, Maricel Salazar, Elina Tripoliti, Ludvic Zrinzo, Jonathan Hyam, Marjan Jahanshahi, Marwan Hariz, Thomas Foltynie
BACKGROUND: Subthalamic nucleus deep brain stimulation (STN-DBS) is an established treatment for selected Parkinson's disease (PD) patients, but therapy is often limited by side effects. Previous studies indicate an inverse relationship of the therapeutic window (TW) to pulse width (PW) settings down to 60μs, but there is limited data available on the effect of shorter PWs. OBJECTIVE: To define the TW of STN-DBS in PD at PW of 30μs (PW30) relative to standard PW settings at 60μs (PW60), and to compare speed of gait and speech intelligibility on the two PW conditions...
2018: Journal of Parkinson's Disease
Adrienne M Keener, Kimberly C Paul, Aline Folle, Jeff M Bronstein, Beate Ritz
BACKGROUND: Parkinson's disease (PD) is a heterogeneous disorder with variability in phenotype and progression. OBJECTIVE: We describe characteristics of PD patients in the largest population-based cohort followed for progression to date, and evaluate clinical risk factors for cognitive impairment and mortality. METHODS: We collected longitudinal data using the Unified Parkinson's Disease Rating Scale (UPDRS), Mini-Mental State Exam (MMSE), and Geriatric Depression Scale (GDS) in 242 new-onset PD patients followed for progression...
2018: Journal of Parkinson's Disease
Karlijn van Dijsseldonk, Ying Wang, Richard van Wezel, Bastiaan R Bloem, Jorik Nonnekes
No abstract text is available yet for this article.
2018: Journal of Parkinson's Disease
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"